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TO THE EDITOR
TP53 (tumor protein 53) responds to
diverse stresses, including ultraviolet
radition-induced DNA damage, and
regulates many downstream genes to
initiate cell-cycle arrest, DNA repair, or
apoptosis (Kaelin, 1999; Robles and
Harris, 2001). TP53 is the most fre-
quently mutated gene in all forms of
human cancers (Hussain and Harris,
1999). In addition to mutations, other
genetic events, such as single nucleo-
tide polymorphisms (SNPs) in the TP53
gene, have been shown to contribute
to the development of cutaneous
Table 1. Genotype and allele frequencies of the TP53 Arg72Pro, p73 G4C144A4T14, and p21 Ser31Arg
polymorphisms and their associations with risk of CM
Patients (n=805) Controls (n=838)1
Crude OR Adjusted OR Adjusted OR
Genotype N % N % P-value2 (95% CI) (95% CI)3 (95% CI)4
TP53 Arg72Pro 0.029
Pro/Pro5 40 5.0 56 6.7 1.00 1.00 1.00
Arg/Pro 300 37.2 350 41.8 1.20 (0.77–1.85) 1.20 (0.78–1.86) 1.28 (0.73–2.23)
Arg/Arg 465 57.8 432 51.5 1.51 (0.98–2.31) 1.50 (0.98–2.30) 1.50 (0.87–2.60)
Arg/Pro+Pro/Pro6 340 42.2 406 48.5 1.00 1.00 1.00
Arg/Arg 465 57.8 432 51.5 1.28 (1.05–1.55) 1.28 (1.05–1.55) 1.21 (0.95–1.56)
Pro allele frequency 0.236 0.276 0.010
P73 G4C144A4T14 0.377
GC/GC 5 468 58.1 497 59.3 1.00 1.00 1.00
GC/AT 287 35.7 302 36.0 1.01 (0.82–1.24) 1.01 (0.82–1.24) 1.01 (0.84–1.41)
AT/AT 50 6.2 39 4.7 1.37 (0.88–2.12) 1.37 (0.88–2.12) 1.33 (0.76–2.33)
GC/AT+GC/GC 5 755 93.8 799 95.4 0.163 1.00 1.00 1.00
AT/AT 50 6.2 39 4.7 1.36 (0.89–2.10) 1.36 (0.89–2.10) 1.29 (0.75–2.24)
AT allele frequency 0.24 0.227 0.401
p21 Ser31Arg 0.815
Ser/Ser5 695 86.3 731 87.2 1.00 1.00 1.00
Ser/Arg 106 13.2 104 12.4 1.07 (0.80–1.43) 1.06 (0.79–1.41) 1.29 (0.88–1.90)
Arg/Arg 4 0.5 3 0.4 1.40 (0.31–6.28) 1.48 (0.33–6.65) 1.33 (0.18–9.82)
Ser/Arg+Arg/Arg 110 13.7 107 12.8 0.592 1.08 (0.81–1.44) 1.07 (0.80–1.42) 1.30 (0.88–1.89)
Arg allele frequency 0.071 0.066 0.618
CI, confidence interval; CM, cutaneous melanoma; OR, odds ratio.
1The observed genotype frequency among the control subjects was in agreement with the Hardy–Weinberg equilibrium (w2 test=1.763, P=0.184 for TP53
Arg72Pro; w2=0.646, P=0.422 for p73 G4C144A4T14; and w2=0.118, P=0.731 for p21 Ser31Arg).
2Two-sided w2 test for either genotype distribution or allele frequency.
3ORs were adjusted for age and sex.
4ORs were adjusted for age, sex, skin color, eye color, hair color, tanning ability, life time number of sunburns with blistering, freckling in the sun as a
child, presence of moles or dysplastic nevi, and family history of cancer (cases=700 and controls=513 due to missing data).
5Individual comparison reference.
6Combine comparison reference.
Abbreviations: CM, cutaneous melanoma; SNP, single nucleotide polymorphism
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melanoma (CM) (Han et al., 2006;
Stefanaki et al., 2007). The TP53 gene
is located at chromosome 17p13.1 and
reportedly has a total of 295 SNPs (http://
www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?
locusId=7157&chooseRs=all). The most
frequently studied SNP is a G-to-C
substitution in codon 72, the only known
common (that is, a minor allele fre-
quency40.05) non-synonymous (poten-
tially functional) SNP that results in an
arginine-to-proline change.
As one of the homologues of TP53,
p73 shares a similar molecular structure
with TP53 (Jost et al., 1997), playing an
important role in carcinogenesis either
in the absence of TP53 or independent
of TP53 (Kaghad et al., 1997; Wang
et al., 2001). Although mutations in p73
are relatively uncommon, there are two
completely linked common SNPs in the
non-coding region of exon 2 (4 G-to-A
and 14 C-to-T) that may influence the
efficiency of translation initiation and
thus may alter cancer risk (Li et al.,
2004; Hu et al., 2005). In addition,
many other genes are involved in cell-
cycle checkpoints, including cyclins,
cyclin-dependent kinases, and cyclin-
dependent kinase inhibitors. For exam-
ple, p21 (Waf1/Cip1/CDKN1A) is a
cyclin-dependent kinase inhibitor and
one of the downstream molecules of
TP53. In response to DNA damage,
TP53 upregulates p21 expression, lead-
ing to either cell-cycle arrest or apop-
tosis (Xiong et al., 1993). The p21 gene
is located on chromosome 6p21.2,
having the least number of SNPs (106
SNPs) (http://www.ncbi.nlm.nih.gov/SNP/
snp_ref.cgi?locusId=1026&chooseRs=all),
among which a C-to-A change in exon
2 is the only common non-synonymous
SNP, resulting in a serine-to-arginine
change at codon 31 that may have a
functional relevance.
Previously, we reported in a rela-
tively small study that the p53 Arg/Arg
genotype was associated with a signifi-
cantly increased risk of melanoma
compared with other genotypes (Shen
et al., 2003). To further extend this
finding and explore its interaction with
variants of other genes, we genotyped
three functional SNPs (that is, TP53
Arg72Pro, p73 G4C144A4T14, and
p21 Ser31Arg) in 805 non-Hispanic
white CM patients and 838 controls
frequency matched by age and sex as
described previously (Shen et al., 2003;
Li et al., 2004, 2005). We found that an
increased risk of CM was associated
with the TP53 Arg/Arg genotype (odds
ratio¼1.28, 95% confidence interval
(95% CI) 1.05–1.55), compared with
the TP53 Pro/ProþArg/Pro genotype—
after adjustment for age and sex—
but not with the p73 G4C144A4T14
or p21 Ser31Arg polymorphism
(Table 1), because variant homozygotes
for p73 and p21 were relatively
uncommon. Further analyses of their
combined genotypes revealed some
non-significantly elevated CM risk
due to reduced sample sizes in the
strata (Table 2), although this large
study confirmed the association
between the p53 Arg/Arg genotype
and increased CM risk (Shen et al.,
2003).
The G-to-C transition at codon 72 in
exon 4 resides in a proline-rich region
of TP53 and results in the Arg to Pro
substitution, which is essential for
Table 2. Combined genotype frequencies of the TP53 Arg72Pro, p73 G4C144A4T14, and p21 Ser31Arg
polymorphisms and their associations with risk of CM
Patients
(n=805)
Controls
(n=838)
Combined genotypes N (%) N (%) P-value1
Crude OR
(95% CI)
Adjusted OR
(95% CI)2
Adjusted OR
(95% CI)3
TP53 Arg72Pro p21 Ser31Arg 0.061
Arg/Pro+Pro/Pro Ser/Ser 287 (35.6) 353 (42.1) 1.00 1.00 1.00
Arg/Arg Ser/Ser 408 (50.7) 378 (45.1) 1.33 (1.08–1.64) 1.32 (1.07–1.63) 1.25 (0.95–1.63)
Arg/Pro+Pro/Pro Ser/Arg+Arg/Arg 53 (6.6) 53 (6.3) 1.23 (0.82–1.86) 1.21 (0.80–1.83) 1.42 (0.83–2.43)
Arg/Arg Ser/Arg+Arg/Arg 57 (7.1) 54 (6.5) 1.30 (0.87–1.94) 1.28 (0.86–1.92) 1.51 (0.88–2.58)
TP53 Arg72Pro p73 G4C144A4T14 0.089
Arg/Pro+Pro/Pro GC/GC+GC/AT 317 (39.4) 385 (45.9) 1.00 1.00 1.00
Arg/Arg GC/GC+GC/AT 438 (54.4) 414 (49.4) 1.29 (1.05–1.57) 1.28 (1.05–1.56) 1.22 (0.94–1.57)
Arg/Pro+Pro/Pro AT/AT 23 (2.9) 21 (2.5) 1.33 (0.72–2.45) 1.34 (0.72–2.46) 1.32 (0.59–2.95)
Arg/Arg AT/AT 27 (3.3) 18 (2.2) 1.82 (0.99–3.37) 1.82 (0.99–3.38) 1.56 (0.73–3.32)
p73 G4C144A4T14 p21 Ser31Arg 0.916
GC/GC+GC/AT Ser/Ser 653 (81.1) 696 (83.0) 1.00 1.00 1.00
GC/GC+GC/AT Ser/Arg+Arg/Arg 102 (12.7) 103 (12.3) 1.06 (0.79–1.42) 1.04 (0.78–1.40) 1.24 (0.84–1.83)
AT/AT Ser/Ser 42 (5.2) 35 (4.2) 1.28 (0.81–2.03) 1.29 (0.81–2.05) 1.17 (0.64–2.12)
AT/AT Ser/Arg+Arg/Arg 8 (1.0) 4 (0.5) 2.13 (0.64–7.11) 2.07 (0.62–6.91) 2.58 (0.63–10.5)
CI, confidence interval; CM, cutaneous melanoma; OR, odds ratio.
1Two-sided w2 test for distributions of genotypic frequencies between the patients and controls.
2ORs were obtained from a multivariate logistic regression model with adjustment for age and sex.
3ORs were adjusted for age, sex, skin color, eye color, hair color, tanning ability, life time number of sunburns with blistering, freckling in the sun as a child,
presence of moles or dyplastic nevi, and family history of cancer (cases=700 and controls=513 due to missing data).
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TP53-mediated apoptosis. However,
bioinformatics analyses by both sorting
intolerant from tolerant and poly-
morphism phenotyping predict TP53
Arg72Pro as a benign change (http://
egp.gs.washington.edu/data/tp53/tp53x.
pph-sift.txt). Our present finding is also
consistent with the result of a recently
published study of 596 Scottish mela-
noma patients and 441 population-
based controls (Povey et al., 2007), in
which the frequency of the TP53 Arg/
Arg genotype was 57.1% in patients
and 53.7% in controls, compared to our
result of 57.8% in 805 patients and
51.5% in 838 controls. However, in a
Greek study (Stefanaki et al., 2007) of
107 patients with CM and 145 controls
and a US Nurses’ Health Study (Han
et al., 2006) of 219 patients with
melanoma and 874 controls, the Arg
variant genotypes were associated with
a non-significantly reduced CM risk.
Given the discrepancies in these small
studies, larger studies are needed to
reconcile these findings.
Little is known about the association
between genetic variations of the p73
gene and risk of CM. Although the
exact functional relevance of the p73
AT variant allele remains unknown,
studies have shown that the GC-to-AT
change may lead to the formation of a
stem–loop structure that may influence
the translation efficacy (Kaghad et al.,
1997). Moreover, it was found that two
N-terminal splice variants of Tap73
(p73Dex2 and p73Dsx2/3) were in-
creased in melanoma (Tuve et al.,
2004). In the present study, our finding
of an association between the AT
homozygous genotype (that is, AT/AT)
and a non-significantly increased risk of
CM suggests that either our sample size
was not large enough to detect a
seemingly small risk, if any, or no risk
was associated with the p73 AT/AT
polymorphism.
As a cyclin-dependent kinases inhi-
bitor, p21 is expected to increase the
proliferation of tumor cells when its
expression decreases. One study sug-
gested that the loss of p21 may con-
tribute to increased tumorigenic
potential in either melanoma cell lines
or human melanomas (Mouriaux et al.,
1998). Because mutations in the p21
gene are infrequent in human melano-
mas (Vidal et al., 1995), we thought
genetic variations in p21 may be an
important factor that could modulate
the p21 gene expression, but few
studies have investigated the role of
p21 polymorphisms in the etiology of
CM. In a study with only 20 patients
and 165 controls (Konishi et al., 2000),
p21 31Arg variant genotypes were
found to be associated with a non-
significantly increased risk of CM,
which was consistent with our finding
in the current, much larger study. The
functional relevance of the p21 Ser31-
Arg polymorphism is unknown, and no
sorting tolerant from intolerant or
polymorphism phenotyping prediction
is available. In this study, the frequency
of homozygous p21 Arg/Arg geno-
type was too few to be meaning-
fully evaluated for its association with
risk of CM, which warrants larger
studies for further validation of our
findings.
This study and research protocol
with patient consent and adherence to
the Declaration of Helsinki Principles
were approved by the MD. Anderson
Institutional Review Board.
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Polymorphism Patterns in the Promoter Region of the
MC1R Gene Are Associated with Development of Freckles
and Solar Lentigines
Journal of Investigative Dermatology (2008) 128, 1588–1591; doi:10.1038/sj.jid.5701192; published online 13 December 2007
TO THE EDITOR
Melanocortin receptor 1 (MC1R), a
G-protein-coupled receptor on mela-
nocytes, plays an important role in
melanogenesis. Binding of a-melano-
cyte-stimulating hormone induces bio-
synthesis of eumelanin (black melanin).
MC1R (OMIM 155555) is highly
polymorphic, and some variants are
related to melanogenic phenotypes. In
Caucasians, specific variants such as
Arg142His, Arg151Cys, Arg160Trp and
Asp294His are strongly associated with
freckles and solar lentigines (Flanagan
et al., 2000; Bastiaens et al., 2001; Box
et al., 2001). All these variants are
known to cause impaired receptor
function in MC1R (Frandberg et al.,
1998; Schioth et al., 1999; Scott et al.,
2002) and/or reduced cell surface
expression of the receptor (Beaumont
et al., 2005; Garcia-Borron et al.,
2005). Decreased apparent sensitivity
to melanocyte-stimulating hormone per
melanocyte thus appears to represent
an important factor in the development
of freckles and solar lentigines.
We recently observed clear associa-
tions of Val92Met and Arg163Gln with
freckles and solar lentigines in Japanese
subjects (Motokawa et al., 2007). Since
the Val92Met variant is known to cause
impaired receptor function (Xu et al.,
1996; Ringholm et al., 2004), this
variant appears to be consistent with
the standard hypothesis. However,
MC1R with the Arg163Gln variant
shows almost identical response to
a-melanocyte-stimulating hormone as
wild-type MC1R receptor (Ringholm
et al., 2004) and no change in expres-
sion on the cell surface (Beaumont
et al., 2005). Since Arg163Gln does
not seem to directly affect sensitivity of
melanocytes to agonist, we created
an alternative hypothesis for the
Arg163Gln variant: the 163Gln allele
may also be associated with other
polymorphic sites in the same locus,
influencing apparent sensitivity of the
melanocyte to melanocyte-stimulating
hormone. Considering these condi-
tions, polymorphism in the promoter
Table 1. Variants in the promoter region of MC1R in Japanese individuals
Nucleotide mutation Number of alleles Allele frequencies
636C4G1 1/494 0.998/0.002
616C4T 1/494 0.998/0.002
490C4T 392/494 0.206/0.794
465C4G1 1/494 0.998/0.002
445G4A 388/494 0.215/0.785
409G4C1 1/494 0.998/0.002
356A4G1 4/494 0.992/0.008
226A4T 388/494 0.215/0.785
488G4A (Arg163Gln) 387/502 0.229/0.771
Genomic DNA was isolated from 10 eyebrow hairs collected from each of 251 randomly selected
Japanese subjects, according to a previously reported method (Motokawa et al., 2006). DNA was
amplified by PCR to generate 882 bp (including 136 bp of the coding region and 746 bp of the
promoter region) using primers F (ttgacagctgagttgctgct) and R (aggaagagcccgtcagagat). PCR conditions
were set as follows: 5min activation at 941C, followed by 35 cycles at 981C for 5 s, 671C for 1min and
721C for 20min for extension. Sequence analysis (1 to 718bp) was performed using an ABI
BigDye Terminator Cycle Sequencing Kit (version 3.1, 4337455; Applied Biosystems, Tokyo, Japan)
using primers A (acccctgtcctccctgag), B (caggaaggcaggagacagag), C (tcagagatggacacctccag), and D
(gacacctcctggcatctacc). The coding region of the G488A allele corresponding to amino-acid residue
163 was sequenced according to previously reported methods (Motokawa et al., 2006). This study
was conducted in compliance with the Declaration of Helsinki Principles. The protocol was approved
by the POLA Ethical Committee, and written informed consent was obtained from all participants.
The G488A allele was detected in all individuals, and the promoter region was completely read in
247 of 251 individuals.
1Previously not identified variants.
Abbreviation: MC1R, melanocortin-1 receptor
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